Pharmacotherapy of Neuropsychiatric Syndromes in Neurologic Disorders: Definitional and Regulatory Aspects
Patients with neurologic diseases may have dosage ranges, side effects, or response profiles of psychotropic agents that differ from those of patients with idiopathic psychiatric disorders. FDA policy now requires demonstration of efficacy, safety, and tolerability of psychotropic agents within neurologic disorders, allowing clinicians to make more rational choices regarding treatment options.
Authors
- Jeffrey L. Cummings (ORCID: https://orcid.org/0000-0001-8944-4158)
- Dilip V. Jeste
Institutions
- University of California, Los Angeles (US)
- UCLA Health (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4141
- Citations
- 8
- Primary Topic
- Attention Deficit Hyperactivity Disorder
- Type
- article
- Field-Weighted Citation Impact
- 0.00